There are numerous ongoing trials to further evaluate the efficacy of BV as monotherapy or combination therapy in PTCLs, including in low CD30-expressing PTCL (NCT02588651, NCT04569032). The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.